logo
Pet drug maker to add death, seizures to warning label on med investigated by Channel 2

Pet drug maker to add death, seizures to warning label on med investigated by Channel 2

Yahoo05-02-2025

A pet drug maker is making a big change on their labels for their new arthritis shot after Channel 2 Action News found pets getting really sick, even dying after getting the drug.
The drug maker Zoetis is now including paralysis and seizures, and even death as possible side effects.
it's a step in the right direction, but some pet owners say it's still not enough for those who lost a pet.
Channel 2 investigative reporter Sophia Choi introduced you to Donna Pope last year after her 14-year-old French bulldog Gumbo died 10 days after getting a Librela shot on Dec. 29, 2023.
'I was just devastated. That was my baby,' Pope said. 'Gumbo was a little spitfire.'
Her dog is one of hundreds of reported deaths linked to the arthritis drug which the FDA approved in May 2023.
Through an open records request, we learned the FDA received at least 825 reports of dog deaths, linked to Librela between May 2023 and June 2024.
Now Zoetis, is updating its label to include death, seizures and paralysis as possible side effects, which they call rare, with more than 1 million dogs in the US getting the shot.
MORE STORIES FROM 2 INVESTIGATES:
Couple says salesmen tricked them into really bad deal on Florida timeshare
Students, teachers upset after popular Atlanta beauty school abruptly closes
Georgia organ donor group works to overcome challenges, stigma of donation
Woman says she went through months of frustration trying to get Sears to fulfill warranty
'This is something that we have prayed for and begged for,' Pope said.
Zoetis said it, 'Has been in active discussions with the FDA about updating the label' and that 'It is not uncommon for products to have label updates as data emerges from real-world use. The company remains confident in the safety and effectiveness of Librela'
Monique Owens said had she known the side effects, she would have never approved the shot for her Cane Corso named Vinny last summer
'It was as if he was drunk walking,' Owens said.
Story continues below document
Librela Prescribing Information 2025 by WSB-TV on Scribd
Vinny is still going through therapy for paralysis, but he's alive.
Pope is still mourning the loss of her dog saying Zoetis needs to do more.
'They've continued to downplay this and that's just not a response that's adequate given the thousands who have lost their lives including my Gumbo,' Pope said.
The FDA contacted Choi directly in December saying they were going to warn vets about the possible serious side effects.
This drug is a big money maker for Zoetis with the company predicting Librela and a version for cats will bring in more than $1 billion in three to five years.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Breyers Ice Creams Recalled After Flavor Containing Life-Threatening Allergen Was Packaged as Another Flavor
Breyers Ice Creams Recalled After Flavor Containing Life-Threatening Allergen Was Packaged as Another Flavor

Yahoo

timean hour ago

  • Yahoo

Breyers Ice Creams Recalled After Flavor Containing Life-Threatening Allergen Was Packaged as Another Flavor

6,668 cases of Breyers Chocolate Truffle Ice Cream across the United States have been recalled by Unilever Manufacturing The affected ice cream cartons actually contain Rocky Road Ice Cream, which contains almonds, a potentially "life-threatening" allergen The U.S. Food and Drug Administration announced the recall on June 10Over 6,600 cases of Breyers Ice Cream have been recalled amid concerns that the product is mislabeled and contains a "life-threatening" allergen. The U.S. Food and Drug Administration confirmed that 6,668 cases of Breyers Chocolate Truffle Ice Cream were voluntarily recalled by Unilever Manufacturing on June 2 in a Tuesday, June 10 statement. The cause for the recall was determined to be "undeclared allergens and mislabeled product." "Rocky Road Ice was packaged with Chocolate Truffle Ice Cream labeled tub and a Rocky Road Ice Cream lid. Tub said 'may contain tree nuts' the lid said it did contain almonds," the FDA clarified about the recall. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! The FDA declared this a Class II recall, which is defined as "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." A representative for Breyers commented on the recall in a statement shared with PEOPLE, saying, "Unilever in the U.S. is voluntarily recalling one lot of Breyers Chocolate Truffle 1.5 quart tubs after some were found to contain Rocky Road ice cream, which includes almonds not listed on the label." The statement continued: "People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products is our top priority. For more information, consumers can visit or call 1-800-931-2826." It is unclear where exactly the cases of ice cream were distributed across the United States. The FDA reported the distribution as targeting "distribution centers and retail locations across the U.S." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. Rocky Road is a flavor of ice cream that contains almonds. Although almonds are considered tree nuts, the label for Breyers Chocolate Truffle Ice Cream only says that the product "may contain tree nuts." The Breyers recall comes a few weeks after nearly 18,000 containers of Wells Dairy ice cream and frozen yogurt were recalled due to contamination with hard plastics. Wells Enterprises, which produces Wells Dairy products, was responsible for the recall, which targeted 22 different flavors of frozen desserts. Read the original article on People

SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors
SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors

Yahoo

timean hour ago

  • Yahoo

SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors

New leadership and recapitalization to accelerate commercialization of proprietary silicon nitride technologies in medical and high-growth markets SALT LAKE CITY, Utah, June 12, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ('SINTX' or the 'Company'), the only FDA-registered producer of implantable silicon nitride and a global leader in advanced ceramics, today announced a renewed corporate vision and strategic plan to accelerate commercialization and unlock the full value of its intellectual property portfolio. This follows the company's successful recapitalization in February 2025 and the restructure of its leadership team and Board of Directors. A Legacy of Innovation in Silicon Nitride In 2008 SINTX Technologies made history with the first FDA-cleared implant material that is neither metal nor plastic—but medical-grade silicon nitride. The initial clearance covered a family of interbody devices and marked a pivotal moment in spinal surgery. These implants offered a unique trifecta of benefits: antimicrobial activity, osteogenic potential, and radiographic translucency. With over 50,000 spinal implants successfully placed worldwide, SINTX has demonstrated the clinical viability and long-term advantages of this revolutionary biomaterial. Today, SINTX remains the industry leader in silicon nitride technology, with 18 issued U.S. patents and 84 pending applications. Known for its strength, biocompatibility, and infection-resistant properties, the company's proprietary ceramic platform has applications across multiple markets—including the $62 billion global orthopedic implant sector, as well as emerging fields like agribiotech and performance textiles. Renewed Vision and Mission SINTX is now taking this one step further by developing next-generation hybrid biomaterials that combine the biological performance of silicon nitride and merging the flexibility, and manufacturability of polymers like PEEK and PEKK. These new composites are being optimized for applications in spine, oral/maxillofacial (OMF), cranio-maxillofacial (CMF), and oncologic reconstruction. 'Our mission is clear: to drive sustainable growth and value creation by collaborating with market leaders who recognize the transformative potential of silicon nitride,' said Mr. Eric Olson, CEO of SINTX Technologies. 'With a strengthened balance sheet and a robust intellectual property portfolio, we are uniquely positioned to accelerate commercialization and deliver superior outcomes for patients, customers, and shareholders alike.' Strategic Initiatives and Market Expansion SINTX is actively pursuing strategic partnerships and licensing opportunities to expand the reach of its technology. The company's near-term focus includes: Joint Ventures: Collaborating with established manufacturers in orthopedics, wound care, agribiotech, and other potential sectors to integrate silicon nitride into next-generation products. IP Monetization: Unlocking value from its extensive patent portfolio through licensing agreements and technology transfer initiatives. Operational Excellence: Enhancing AI supported 3D manufacturing capabilities at its FDA cleared and ISO certified headquarters to support anticipated growth and ensure the highest quality standards. Commitment to Stakeholders As SINTX enters this new era, the Company reaffirms its commitment to transparency, disciplined execution, and long-term value creation for all stakeholders. 'We are grateful for the continued support of our shareholders and partners,' said Mr. Olson. 'Together, we will realize the full potential of silicon nitride and secure SINTX's position as a leader in advanced ceramics. For more information, please visit About SINTX Technologies, Inc. Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. For more information on SINTX Technologies or its materials platform, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ('PSLRA') that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,' "future," "likely," "may," "should," "will" and similar references to future periods. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. Forward looking statements include our efforts to develop next-generation hybrid biomaterials, our expectation that will drive sustainable growth and value creation, and that we will expand the reach of our technology pursuing strategic partnerships and licensing opportunities. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in developing and commercializing medical device technologies. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law. Business and Media Inquiries for SINTX:SINTX Technologies, Inc. 801.839.3502IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Sofinnova taps NVIDIA to bolster portfolio companies' computational power
Sofinnova taps NVIDIA to bolster portfolio companies' computational power

Yahoo

timean hour ago

  • Yahoo

Sofinnova taps NVIDIA to bolster portfolio companies' computational power

Sofinnova Partners has partnered with NVIDIA in a move intended to equip its life sciences portfolio companies with faster processing speeds for processing complex biological datasets. The French VC said that amid increasing demand for computational resources driven by artificial intelligence (AI), its portfolio companies will now be able to access NVIDIA Blackwell and related graphical processing units (GPU) offered by the technology giant via NVIDIA DGX Cloud Lepton, an AI platform and marketplace that connects developers to global AI infrastructure. According to a report by GlobalData, the global revenue for AI platforms across healthcare is forecast to reach $18.8bn by 2027. Sofinnova's most recent fund is focused on digital medicine. By partnering with Nvidia, its portfolio companies in the area, including startups BioCorteX, Bioptimus, and Cure51, will be to process biological datasets and run computational models to complete tasks 'within days' that would previously have taken months through Cloud Lepton, the VC said. Sofinnova Partners' chairman and managing partner Antoine Papiernik commented: "This collaboration supercharges computation for life sciences innovation. The convergence of biology, AI, computation, and data isn't just our investment thesis – it's the defining battleground of the next decade. 'By securing access to Nvidia's infrastructure, we're not just funding companies; we're empowering them with the computational backbone needed to outperform incumbents and redefine what's possible in drug discovery, precision medicine, and scalable solutions that address both human health and sustainability." In March, Sofinnova's life sciences fund reached €4bn ($4.6bn). Papiernik said that following the milestone, the VC plans to invest in 50 to 60 new companies, adding to the more than 100 life sciences companies it has invested in to date, including the cardiovascular medtech company Shockwave Medical. Sofinnova also has Sofinnova AI. Launched in 2023 and combining data analytics and machine learning, the VC has stated that this fund is intended to strengthen its ability to identify innovations and accelerate the development of life sciences companies. News of the partnership coincides with Nvidia's GTC conference, taking place in Paris, France from 10-12 June. During a presentation at the event, Nvidia CEO Jensen Huang said: 'Europe isn't just adopting AI — it's building it.' Notable healthcare announcements at the event included a new collaboration between Nvidia and Novo Nordisk to accelerate drug discovery efforts through AI use cases, with Nvidia's aim to create customised AI models and agents that Novo Nordisk can use ind early research and clinical development. Nvidia also announced a new partnership with GE HealthCare intended to advance innovation in autonomous imaging with a focus on developing autonomous X-ray technologies and ultrasound applications. "Sofinnova taps NVIDIA to bolster portfolio companies' computational power" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store